tiprankstipranks
Trending News
More News >
Varex Imaging Corporation (VREX)
NASDAQ:VREX
Advertisement

Varex Imaging (VREX) AI Stock Analysis

Compare
177 Followers

Top Page

VREX

Varex Imaging

(NASDAQ:VREX)

Rating:58Neutral
Price Target:
$11.00
▲(2.90% Upside)
Varex Imaging's overall stock score reflects significant financial challenges, with declining revenues and profitability being the most impactful factors. Despite strong technical indicators suggesting short-term bullish momentum, the negative valuation metrics and mixed earnings call results highlight ongoing risks. The company's ability to address these financial and operational challenges will be crucial for future performance.

Varex Imaging (VREX) vs. SPDR S&P 500 ETF (SPY)

Varex Imaging Business Overview & Revenue Model

Company DescriptionVarex Imaging Corporation designs and manufactures X-ray imaging components. The company operates in two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components comprising X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, 3D reconstruction and computer-aided diagnostic software, collimators, automatic exposure control devices, generators, heat exchangers, ionization chambers, and buckys. This segment's products are used in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy, oncology, CT, cardiac, surgery, dental, computer-aided detection, and other diagnostic radiography uses. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital detectors, and high voltage connectors for use in security and industrial inspection applications, such as airport security, cargo screening at ports and borders, and nondestructive testing and examination in various applications. Varex Imaging Corporation sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was founded in 2016 and is based in Salt Lake City, Utah.
How the Company Makes MoneyVarex Imaging generates revenue primarily through the sale of its imaging products and systems. Key revenue streams include the sale of X-ray tubes, flat panel detectors, and related imaging components, which are utilized in medical imaging equipment and industrial applications. Additionally, the company benefits from ongoing service and support contracts, which provide a steady income stream. Varex has established significant partnerships with major medical equipment manufacturers, allowing them to integrate their components into larger systems, which enhances their market reach and contributes to revenue growth. The company also invests in research and development to innovate and expand its product offerings, further driving revenue through new technology introductions.

Varex Imaging Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q3-2025)
|
% Change Since: 36.88%|
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Neutral
While the company demonstrated strong performance in exceeding revenue guidance and reducing debt, challenges such as a decline in the Medical segment revenue, high operating expenses due to goodwill impairment, and decreased cash reserves balanced the positive aspects. The Industrial segment showed growth, and there was significant progress in new technologies, but these were tempered by regional revenue declines and sales below trend in certain modalities.
Q3-2025 Updates
Positive Updates
Revenue Exceeds Guidance
Third quarter revenue of $203 million exceeded the high end of the company's guidance.
Industrial Segment Performance
The Industrial segment experienced continued strong demand, with a 1% increase year-over-year. Key growth drivers included security screening and cargo inspection components.
Reduction in Debt
The company successfully paid off $200 million in convertible notes, reducing overall debt burden and simplifying capital structure.
Photon Counting Technology Progress
Progress in photon counting technology with OEMs integrating it into new systems, and the launch of the THOR detector for high-speed industrial CT imaging.
Strong Cargo Systems Orders
Year-to-date bookings for cargo inspection systems reached over $55 million, with new orders for $17 million announced in the quarter.
Medical Segment Growth in Certain Modalities
Sales in oncology and mammography modalities were above their respective sales trends.
Negative Updates
Revenue Decline in Medical Segment
Total revenue was down 3% year-over-year with the Medical segment down 4%.
High Operating Expenses
Operating expenses increased by $90 million compared to the third quarter of fiscal '24, primarily due to a non-cash goodwill impairment charge of $94 million.
Decreased Cash Position
Cash, cash equivalents, and marketable securities decreased by $73 million from the prior quarter, primarily due to debt repayment.
Decline in EMEA and APAC Revenues
EMEA revenues were down 2%, while APAC revenues decreased 8% year-over-year.
Fluoroscopy Sales Below Trend
Sales in the fluoroscopy modality were below its sales trend.
Company Guidance
During the Varex Imaging Corporation's third quarter earnings call for fiscal year 2025, the company reported a revenue of $203 million, which exceeded the high end of their guidance. The Industrial segment showcased continued strength, with a 1% year-over-year increase, while the Medical segment experienced a 4% decline. Notably, sales in China rebounded as tariffs decreased to 55%, allowing the company to meet shipment demands that had been previously paused due to higher tariffs. The non-GAAP gross margin was reported at 34%, 100 basis points higher than the same quarter last year, primarily due to a favorable product sales mix and reduced tariff-related expenses. Non-GAAP earnings per share increased by $0.04 to $0.18 compared to the previous year. The company ended the quarter with $153 million in cash, cash equivalents, and marketable securities, reflecting a $73 million decrease due to repayment of $200 million in convertible notes. Looking ahead, Varex provided guidance for the fourth quarter, projecting revenues between $210 million and $230 million, with non-GAAP earnings per share expected to range from $0.10 to $0.30.

Varex Imaging Financial Statement Overview

Summary
Varex Imaging shows moderate revenue growth and strong cash flow management, but faces profitability challenges with persistent net losses. The balance sheet is stable, though higher leverage could pose risks.
Income Statement
65
Positive
Varex Imaging shows moderate revenue growth in the TTM with a slight increase compared to the previous annual period. However, the company reports a negative net income margin due to losses, impacting profitability. The gross profit margin is stable, indicating effective cost management, though EBIT and EBITDA margins show room for improvement.
Balance Sheet
70
Positive
The company's balance sheet indicates a reasonable debt-to-equity ratio, although leverage is on the higher side, which could pose a risk in a rising interest rate environment. The equity ratio is stable, suggesting a balanced asset structure. Return on equity is negative due to net losses, highlighting profitability challenges.
Cash Flow
72
Positive
Varex Imaging demonstrates strong free cash flow growth in the TTM, reflecting improved cash management. The operating cash flow to net income ratio is robust, indicating good cash generation relative to reported earnings. However, the free cash flow to net income ratio highlights the impact of negative earnings on cash flow efficiency.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue821.40M811.00M893.40M859.40M818.10M738.30M
Gross Profit279.80M256.90M290.30M283.50M271.50M190.20M
EBITDA-18.20M62.90M94.70M119.10M109.30M-1.70M
Net Income-132.50M-47.70M48.20M30.30M17.40M-57.90M
Balance Sheet
Total Assets1.07B1.22B1.25B1.18B1.15B1.14B
Cash, Cash Equivalents and Short-Term Investments152.60M200.50M193.90M89.40M144.60M100.60M
Total Debt24.80M470.40M469.50M436.40M459.40M484.50M
Total Liabilities603.90M667.80M668.60M637.70M651.00M673.70M
Stockholders Equity455.30M535.10M567.70M533.40M483.30M451.70M
Cash Flow
Free Cash Flow36.40M20.40M87.70M-4.40M77.50M-10.30M
Operating Cash Flow59.60M47.30M108.40M16.90M92.60M13.20M
Investing Cash Flow-3.00M-27.50M-44.90M-48.40M-16.20M-26.90M
Financing Cash Flow-76.10M-3.30M-200.00K-23.80M-32.30M83.60M

Varex Imaging Technical Analysis

Technical Analysis Sentiment
Positive
Last Price10.69
Price Trends
50DMA
8.17
Positive
100DMA
8.42
Positive
200DMA
11.23
Negative
Market Momentum
MACD
0.47
Negative
RSI
77.53
Negative
STOCH
91.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VREX, the sentiment is Positive. The current price of 10.69 is above the 20-day moving average (MA) of 8.01, above the 50-day MA of 8.17, and below the 200-day MA of 11.23, indicating a neutral trend. The MACD of 0.47 indicates Negative momentum. The RSI at 77.53 is Negative, neither overbought nor oversold. The STOCH value of 91.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VREX.

Varex Imaging Risk Analysis

Varex Imaging disclosed 31 risk factors in its most recent earnings report. Varex Imaging reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Varex Imaging Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$288.57M21.9510.79%17.11%45.34%
58
Neutral
$438.65M-25.57%-1.36%-479.49%
54
Neutral
$542.17M-15.36%-0.02%-1196.44%
51
Neutral
kr6.00B8.78-28.70%2.24%51.61%19.20%
46
Neutral
$138.61M271.41%45.50%53.07%
46
Neutral
$385.67M-102.61%5.94%25.16%
42
Neutral
$284.06M-32.87%17.36%9.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VREX
Varex Imaging
10.69
-1.89
-15.02%
SRDX
SurModics
37.99
-1.73
-4.36%
SENS
Senseonics Holdings
0.48
0.07
17.07%
VMD
Viemed Healthcare
7.33
0.13
1.81%
NNOX
Nano-X Imaging
4.55
-2.71
-37.33%
TLSI
TriSalus Life Sciences
3.95
-1.94
-32.94%

Varex Imaging Corporate Events

Legal ProceedingsBusiness Operations and StrategyRegulatory Filings and Compliance
Varex Imaging Faces Anti-Dumping Investigation in China
Negative
Apr 4, 2025

Varex Imaging Corporation is aware of an anti-dumping investigation initiated by China’s Ministry of Commerce concerning imports of certain medical CT X-ray tubes from the United States and India. Although the company has not received formal notice, it plans to cooperate if notified and believes it complies with competition laws, highlighting potential impacts on its operations and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 14, 2025